相关实验视频

Updated: Jun 10, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

免疫检查点抑制剂的可互换性:迫切需要采取行动

Michiel Zietse¹, Roelof W F van Leeuwen², Sahar Barjesteh van Waalwijk van Doorn-Khosrovani³

¹Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands.

The Lancet. Oncology

|October 17, 2024

概括

关于PD-1和PD-L1抑制剂的治疗互换性的不确定性影响了临床决策和预算. 新的研究,包括对比试验,对于评估这些癌症免疫疗法至关重要.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
卫生经济学卫生经济学

背景情况:

关于编程细胞死亡蛋白1 (PD-1) 和编程死亡配体1 (PD-L1) 抑制剂的治疗互换性存在不确定性.
这种不确定性使临床决策和医疗保健资源分配变得复杂.

研究的目的:

综合评估PD-1和PD-L1抑制剂的监管环境,市场动态和经济影响.
确定当前临床试验设计中的挑战,以评估治疗互换性.
为未来的研究提出建议,以澄清这些药物的可互换性.

主要方法:

对PD-1和PD-L1抑制剂的现行监管框架的审查.
分析现有的临床试验设计及其局限性.
探索市场竞争和定价策略.

主要成果:

对于PD-1和PD-L1抑制剂的监管环境是分散的.
目前的临床试验设计往往没有信息来评估治疗互换性.
市场竞争和定价显著影响医疗保健预算.

结论:

需要进行研究以确定PD-1和PD-L1抑制剂的可互换性.
推的研究包括头对头的随机对照试验,标准化的间接比较设计,以及结合单一治疗手臂的试验.
建议在试验设计和评估中采用近等价的框架.

更多相关视频

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...